CLASSIFY-OMM: Multicenter Rare Disease Cohort for T-Stage Reclassification and Molecular Subtyping-Based Precision Therapy in Oral Mucosal Melanoma
Trial Snapshot
- Phase
- Not Applicable
- Status
- Not yet recruiting
- Sponsor
- Enrollment
- 1,100
- Locations
- 1
Study Overview
Brief Summary
This bidirectional cohort study (retrospective + prospective) focuses on three key challenges in oral mucosal melanoma (OMM): clinical staging based on depth of invasion (DOI), molecular subtyping, and precision therapy. By integrating DOI-driven T-stage reclassification, genomic profiling, and longitudinal follow-up, we aim to build a population-specific, high-quality evidence resource to support refined staging, CDK4-targeted treatment, and prognostic modeling for Chinese OMM patients.
Detailed Description
Study Design This is a multicenter, bidirectional (retrospective + prospective) observational cohort study designed to establish a high-quality evidence platform for oral mucosal melanoma (OMM), a rare malignancy with high aggressiveness and poor prognosis. The study is conducted at four tertiary hospitals in China: Shanghai Ninth People's Hospital (lead center), Air Force Medical University Stomatological Hospital, Xiangya Hospital of Central South University, and Sun Yat-sen Memorial Hospital of Sun Yat-sen University.
Study Population The cohort will include a total of 1,100 Chinese patients with histopathologically confirmed primary OMM.
Retrospective cohort (n=800): Patients diagnosed between January 2015 and June 2025, with complete medical records, pathological slides, and available follow-up data.
Prospective cohort (n=300): Consecutive newly diagnosed patients enrolled from July 2025 to December 2028, after providing written informed consent.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Other
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Histopathologically confirmed primary oral mucosal melanoma (WHO criteria);
- •Primary site: oral mucosa (palate, gingiva, sublingual, buccal, hard palate, floor of mouth);
- •Receiving or planning standard treatment (surgery, radiotherapy, chemotherapy, immunotherapy, or targeted therapy);
- •Age ≥18 years, any sex;
- •Complete clinical data with pathology, imaging, and records (retrospective) OR willingness for long-term follow-up (prospective);
- •Signed informed consent (prospective) or data meeting ethical waiver (retrospective).
Exclusion Criteria
- •Primary melanoma originating from skin, eye, esophagus, or other non-oral mucosal sites;
- •Secondary/metastatic oral mucosal melanoma (primary not in oral cavity);
- •Unavailable key clinical information (surgical records, pathology, imaging);
- •Prior or concurrent other malignancy interfering with prognosis;
- •Severe mental/cognitive disorders or poor compliance;
- •Severe comorbidities (heart failure, liver/renal failure) affecting treatment or survival analysis;
- •Patient refusal or withdrawal of informed consent.
Investigators
ren guoxin
PI
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University